SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

SLENYTO is the first and only prescription melatonin in Canada and the only melatonin authorized for sale by Health Canada for children and adolescents 2 to <18 years of age. Autism Spectrum Disorder affects approximately 1 in 44 (2.25%) Canadian children and youth; 60-86% of children with ASD experience sleep irregularities.

SCIENTURE has commercially launched REZENOPY, its 10 mg naloxone nasal spray, and fulfilled initial purchase orders to U.S. pharmaceutical wholesalers, moving its second FDA-approved commercial product into nationwide distribution.

Key Investor Takeaways

• SCIENTURE has begun profitable sales of REZENOPY, transforming the product from market research to active distribution.
• REZENOPY is the highest-dose FDA-approved naloxone hydrochloride nasal spray in the U.S., bringing 10 mg in a single-use tools.
• The organization cited an around $143 million U.S. naloxone market covering 9.8 million units, based on IQVIA MAT June 2026 information.
• Commercial payer coverage has the strenth to reach more than 100 million covered lives, while GPO agreements offer access to over 5,000 medical care services.
• REZENOPY becomes SCIENTURE's second FDA-approved commercial product, increasing the company's portfolio of revenue-generating assets.

Why SCNX Stock Is in Focus

SCIENTURE has satisfied its first REZENOPY purchase orders to U.S. healthcare wholesalers and commenced nationwide distribution, creating the start of commercial execution for the product.

REZENOPY is approved for the emergency management of known or suspected opioid overdose in adult and pediatric patients. The product delivers 10 mg of naloxone hydrochloride in a single-use nasal spray, creating it the highest-dose FDA-approved naloxone hydrochloride nasal spray available in the United States, according to the organization.

SCIENTURE has deployed an intended national sales team targeting hospitals, emergency healthcare solution, rehabilitation centers, pharmacies, public health agencies and other medical care providers.

The organization enters the launch with commercial payer coverage suggestively reaching more than 100 million covered lives. Its GPO agreements offers access to more than 5,000 medical care facilities, which SCIENTURE says shows potential penetration of over 60% of the U.S. institutional naloxone market.

Why This Matters for Investors

The commercial launch changes the REZENOPY story from one centred on regulatory approval and market preparation to one focused on acceptance and revenue generation

That distinction significant for because REZENOPY increasing the number of FDA-approved products in its commercial portfolio to two. Management expects the product to use infrastructure previously established across production, supply chain, distribution and market access, significantly increasing the strategic value of those existing capabilities as the portfolio increasing.

The addressable market offers another point of focus. SCIENTURE cited IQVIA information presenting approximately $143 million in annual U.S. naloxone sales across 9.8 million units as of June 2026. The combination of payer coverage, institutional purchasing agreements and a intended sales force gives the organization established channels through which it pursues that opportunity.

Though, access does not itself establish adoption. For investors, the next stage will likely based on SCIENTURE's capability to translate its distribution footprint and institutional availability into product uptake. The release does not offer REZENOPY revenue guidance or sales targets, leaving commercial performance as an imperative measure of implementation.

According to Towards Healthcare, the U.S. pharmaceutical market is projected to grow significantly, with estimates indicating the market size will increase from USD 553.55 billion in 2026 to approximately USD 965 billion by 2035. The market is expanding at a CAGR of 6.37% between 2026 and 2035. Advance pharmaceutical solution supports to manage chronic diseases, avoids medication challenges, and guide accurate drug use for better health outcome. Pharmaceutical sciences drive drug discovery, advancement, and delivery, developing worldwide medical care through innovative advancement. Pharmaceutical care goal to enhance a patient's health-associate quality of life while achieving favorable medical care outcomes at a reasonable expenses. Pharmaceutical solutions are significant parts of modern medicalcare. They secure safe therapeutics use, manage drug distribution, and enhance patient health. These solution span from local drug stores to large hospital care technology.

What to Watch Next

Attention recently shifts to evidence of REZENOPY acceptance following the initial acquisition orders. Updates on institutional uses, additional sector access and the product's influence to SCIENTURE's revenue supports to indicate the efficiency of the launch.

Investors also watch whether SCIENTURE increases REZENOPY's commercial reach through the remainder of 2026 and how efficiently its presenting infrastructure supports growth in a wider portfolio of marketed field pharmaceutical products.

A recent report by Towards Healthcare highlights that the U.S. pharmaceutical market is growing, as significant advantages of pharmaceutical services lies in their ability to positively influence health results. Through different initiatives and interventions, pharmacists plays a significant role in increasing patient safety, enhancing therapeutics adherence, and avoiding drug interactions and adverse effects. The strength for drug interactions and adverse reactions is a constant challenges, specifically for individuals with complex medication regimens. Pharmacists supports avoids this challenges by conducting comprehensive therapeutics reviews, detection potential interactions, and partnering with medical care providers to develop safer substitutes or adjust dosage regimens. This proactive stratergy avoids harmful drug interactions and minimizes the occurrence of side effects.